Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management
Authors:
Open Access
- 12 February 2025
- journal article
- Published by Elsevier in European Urology Open Science
- Vol. 72, 46-53
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health National Cancer Institute
This publication has 23 references indexed in Scilit:
- The oncologic risk of magnetic resonance imaging‐targeted and systematic cores in patients treated with radical prostatectomyCancer, 2023
- Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active SurveillanceEuropean Urology Focus, 2022
- Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate TissueUrology, 2022
- Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and MetaregressionEuropean Urology Oncology, 2022
- Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic reviewWorld Journal of Urology, 2021
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2021
- Three Things About Gleason Grading That Just About Everyone Believes But That Are Almost Certainly WrongUrology, 2020
- Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityJAMA Oncology, 2020
- EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)European Urology, 2019
- Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate CancerJournal of Urology, 2019